CD19 CAR-T细胞疗法治疗难治性血清阳性类风湿关节炎:1期试验
COMPARE试验1/2期非随机1期部分评估miv-cel(自体全人源CD19 CAR-T)治疗6例重度难治性ACPA阳性RA患者,单次输注后随访36-52周。主要终点为4周内CRS、ICANS及AE的发生率和严重程度,结果显示CRS均为1-2级,无ICANS或严重AE,1例剂量限制性毒性(3级转氨酶升高)无后遗症缓解。疾病活动度全部改善,中位DAS28-CRP降低34%,3/6达DAS28-CRP缓解和ACR70应答。
要点
- miv-cel单次输注在难治性ACPA阳性RA中短期安全性可接受,CRS限于1-2级。
- 无ICANS或严重AE,1例3级转氨酶升高剂量限制性毒性无后遗症缓解。
- 停用免疫抑制后疾病活动度全部改善,中位DAS28-CRP降低34%,3/6达缓解和ACR70。
核心结论
- CD19 CAR-T细胞疗法miv-cel在治疗难治性RA中显示可接受的短期耐受性,支持进一步评估。
研究设计与样本
- COMPARE试验1/2期非随机1期部分,纳入6例(3男3女)重度难治性ACPA阳性RA患者。
- 患者停用所有DMARD后接受标准淋巴细胞清除,单次输注miv-cel,随访36-52周。
- 主要终点为治疗后4周内CRS、ICANS和AE的发生率及严重程度。
主要发现
- CRS发生于所有患者,仅限于1级和2级事件。
- 无ICANS或严重AE发生;记录到1例剂量限制性毒性(3级转氨酶升高),无后遗症缓解。
- CAR-T导致血液和组织中CD19+ B细胞耗竭,自身抗体持续下降,4/6例抗MCV ACPA血清转换,5/6例RF IgM血清转换。
- 尽管停用免疫抑制治疗,所有患者疾病活动度改善,最新随访时中位DAS28-CRP降低34%,3/6例达DAS28-CRP缓解和ACR70应答。
关键数值与推荐
- 主要终点达到可接受的安全性结果,允许推进至2期。
- CRS限于1级和2级;1例3级转氨酶升高为剂量限制性毒性。
- 中位DAS28-CRP降低34%;3/6例达DAS28-CRP缓解和ACR70应答。
临床怎么用
- 对于重度难治性ACPA阳性RA,CD19 CAR-T可能作为停用免疫抑制后的单次输注选择,需监测CRS和转氨酶。
局限性
- 非随机1期部分,样本量仅6例,随访36-52周,为短期安全性及探索性疗效数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric antigen receptor (CAR) T cell-mediated B cell depletion has demonstrated efficacy in several autoimmune diseases. Here we report clinical and molecular data obtained during the nonrandomized phase 1 part of the phase 1/2 COMPARE trial, evaluating safety and efficacy of mivocabtagene autoleucel (miv-cel), an autologous fully human CD19 CAR T cell therapy, in rheumatoid arthritis (RA). Six patients (three men, three women) with severe, treatment-refractory, anti-citrullinated protein antibody (ACPA)-positive RA received a single infusion of miv-cel after stopping all disease-modifying antirheumatic drug treatments and after standard lymphodepletion therapy. Patients were followed for 36-52 weeks for safety and efficacy. Primary endpoints were the incidence and severity of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and adverse events (AEs) within the first 4 weeks after treatment. Secondary and explorative endpoints assessed clinical efficacy and cellular and humoral immune responses. CRS occurred in all patients and was limited to grade 1 and 2 events. No ICANSs or serious AEs occurred; one dose-limiting toxicity was recorded (grade 3 transaminase elevation, resolved without sequelae). The primary endpoint was met with acceptable safety findings, allowing advancement to phase 2. CAR T cell therapy resulted in depletion of CD19+ B cells across blood and tissue, coinciding with a continuous decline of autoantibodies with seroconversion in four of the six patients for ACPAs against mutated citrullinated vimentin and five of six for rheumatoid factor immunoglobulin M. Despite cessation of immunosuppressive treatments, disease activity improved in all patients (median 34% DAS28-CRP reduction at the latest follow-up with DAS28-CRP remission and American College of Rheumatology 70% response in 3 of 6 patients). CD19 CAR T cells showed acceptable short-term tolerability in patients with treatment-refractory RA, justifying further evaluation. ClinicalTrials.gov identifier: NCT06475495 .
引用
- Albach FN, Rehm MC, Hütter-Krönke ML, et al. CD19 CAR T cell therapy for treatment-refractory seropositive rheumatoid arthritis: a phase 1 trial. Nat Med. 2026. PMID: 42661098. doi:10.1038/s41591-026-04603-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。